SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-17-000607
Filing Date
2017-08-03
Accepted
2017-08-03 14:17:09
Documents
3
Group Members
ORBIMED CAPITAL GP VI LLCSAMUEL D. ISALY

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss53950_sc13d.htm SC 13D 101551
2 JOINT FILING AGREEMENT ss53950_ex9901.htm EX-99.1 10062
3 FORM OF LOCK-UP AGREEMENT ss53950_ex9902.htm EX-99.2 33296
  Complete submission text file 0000947871-17-000607.txt   146661
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 201 ELLIOTT AVE. WEST, SUITE 230 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. WEST, SUITE 230 SEATTLE WA 98119 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Subject) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88896 | Film No.: 171004306
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1